|
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
|
08 August 2019 |
|
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
|
23 July 2019 |
|
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
|
19 June 2019 |
|
Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences
|
03 June 2019 |
|
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
|
01 May 2019 |
|
Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
|
11 March 2019 |
|
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
|
06 March 2019 |
|
Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference
|
05 March 2019 |
|
Marinus Announces Leadership Transition
|
26 February 2019 |
|
Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference
|
20 February 2019 |
|
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
05 February 2019 |
|
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
25 January 2019 |
